Humoral and cell-mediated immune responses are blunted after SARS-CoV-2 vaccination
in patients with a history of CD20 B-cell-depleting treatment.1 However, vaccination
induces SARS-CoV-2-specific antibodies in patients treated with rituximab once peripheral
…